U.S. MarketsAugust 3 at 03:49 PM

Eli Lilly (LLY) spokesperson confirmed that it will allow other patients to apply for early access to retatrutide, Stat News reports

StockNow breaking-news AI analysis

Eli Lilly confirms expanded early access for retatrutide, its potent triple agonist for obesity. Phase 3 results show record-breaking efficacy, with FDA filing targeted for Q1 2027.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday

U.S. Economy